<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857115</url>
  </required_header>
  <id_info>
    <org_study_id>IST-CAR-561</org_study_id>
    <nct_id>NCT01857115</nct_id>
  </id_info>
  <brief_title>Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)</brief_title>
  <acronym>wCCyd</acronym>
  <official_title>A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Myeloma Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione EMN Italy Onlus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Myeloma Network</source>
  <brief_summary>
    <textblock>
      This protocol is a phase I/II multicenter study designed to assess the safety and the&#xD;
      efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM)&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENT PERIOD Patients will start the induction treatment with wCCyd, as soon as the&#xD;
      screening visits of the pre-treatment period have been terminated.&#xD;
&#xD;
      Each cycle will be repeated every 28 days for a total of 9 courses.&#xD;
&#xD;
      Treatment schedule for 9 cycles of induction:&#xD;
&#xD;
      Phase I:&#xD;
&#xD;
      In the phase I part of the study, the following dose levels of carfilzomib will be studied&#xD;
      with constant doses of dexamethasone and cyclophosphamide to define the maximum tolerated&#xD;
      dose (MTD):&#xD;
&#xD;
      Level -1&#xD;
&#xD;
        1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.&#xD;
&#xD;
        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9,15-16, 22-23.&#xD;
&#xD;
        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36 mg/m2&#xD;
           on days 8, 15 of Cycle 1, then for all subsequent doses 36 mg/m2 IV once daily on days&#xD;
           1, 8, 15, followed by 14-day rest period (day 16 through 28).&#xD;
&#xD;
      Level 0 (starting dose)&#xD;
&#xD;
        1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.&#xD;
&#xD;
        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9,15-16, 22-23.&#xD;
&#xD;
        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 45 mg/m2&#xD;
           on days 8, 15 of Cycle 1, then for all subsequent doses 45 mg/m2 IV once daily on days&#xD;
           1, 8, 15, followed by 14-day rest period (day 16 through 28).&#xD;
&#xD;
      Level +1&#xD;
&#xD;
        1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.&#xD;
&#xD;
        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9,15-16, 22-23.&#xD;
&#xD;
        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 56 mg/m2&#xD;
           on days 8, 15 of Cycle 1, then for all subsequent doses 56 mg/m2 IV once daily on days&#xD;
           1, 8, 15, followed by 14-day rest period (day 16 through 28).&#xD;
&#xD;
      Level +2&#xD;
&#xD;
        1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.&#xD;
&#xD;
        2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9,15-16, 22-23.&#xD;
&#xD;
        3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 70 mg/m2&#xD;
           on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days&#xD;
           1, 8, 15, followed by 14-day rest period (day 16 through 28).&#xD;
&#xD;
      Patients will be observed during the first cycle of therapy for the assessment of side&#xD;
      effects and observation of DLTs. Dose escalation will proceed as follows:&#xD;
&#xD;
        -  3 patients will be entered at dose level 0.&#xD;
&#xD;
        -  If 0/3 patients experience DLT, dose escalation will continue.&#xD;
&#xD;
        -  If 1/3 patients experience DLT, 3 additional patients will be added to this cohort (max&#xD;
           6).&#xD;
&#xD;
        -  If no further patients experience DLT (1/6) dose escalation will continue.&#xD;
&#xD;
        -  If 2/6 patients experience DLT, the MTD will have been exceeded and the MTD will be the&#xD;
           previous dose at which &lt; 2/6 experienced DLT.&#xD;
&#xD;
        -  If 2/3 patients experience a DLT at any given dose, the MTD will have been exceeded and&#xD;
           the MTD will be the preceding dose at which &lt; 2/6 (or 1/3) patients experienced a DLT.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      The dose used to treat patients in the phase II will be the MTD defined in the phase I of the&#xD;
      study.&#xD;
&#xD;
      MAINTENANCE PERIOD At the end of the induction phase, patients will start the maintenance&#xD;
      phase with Carfilzomib at the MTD defined by the phase I study IV once daily on days 1, 8, 15&#xD;
      until progression or intolerance.&#xD;
&#xD;
      Treatment schedule for maintenance until progression or intolerance:&#xD;
&#xD;
      Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Dose-limiting toxicity (DLT)</measure>
    <time_frame>1 year</time_frame>
    <description>Non-hematologic:&#xD;
Grade2 neuropathy with pain&#xD;
any Grade 3 toxicity (excluding nausea, vomiting, diarrhea)&#xD;
Grade3 nausea, vomiting, or diarrhea despite maximal antiemetic/antidiarrheal therapy&#xD;
Grade4 fatigue lasting for ≥7days&#xD;
Any non-hematologic toxicity requiring a dose reduction within Cycle1&#xD;
Inability to receive Day 1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.&#xD;
Hematologic:&#xD;
Grade 4 neutropenia (ANC&lt;0.5x109/L) lasting for ≥7days&#xD;
Febrile neutropenia (ANC&lt;1.0x109/L with a fever ≥38.3ºC)&#xD;
Grade 4 thrombocytopenia (platelets&lt;25.0x109/L) lasting ≥7 days despite dose delay&#xD;
Grade 3-4 thrombocytopenia associated with bleeding&#xD;
Any hematologic toxicity requiring a dose reduction within Cycle1&#xD;
Inability to receive Day1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial Response (PR)</measure>
    <time_frame>1 year</time_frame>
    <description>The primary efficacy endpoints will be assessed by considering partial response (PR) following the proposed regimen, at the end of third cycle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free-survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine progression free-survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy (TTNT)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the time to next therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses</measure>
    <time_frame>3 years</time_frame>
    <description>Determine whether responses obtained with wCCyd treatment are associated with a prolongation of PFS, in comparison with non-responding patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response and survival</measure>
    <time_frame>3 years</time_frame>
    <description>Determine whether tumor response and survival might significantly change in particular subgroups of patients defined on prognostic factors (β2-microglobulin, C-reactive protein (CRP), FISH, gene expression profile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the benefit on PFS and OS of maintenance with Carfilzomib&#xD;
Determine the benefit on tumor load of maintenance with Carfilzomib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CCyd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment schedule for 9 cycles of induction:&#xD;
Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.&#xD;
Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.&#xD;
Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).&#xD;
Treatment schedule for maintenance until progression or intolerance:&#xD;
Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>CCyd</arm_group_label>
    <other_name>Krypolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>CCyd</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>CCyd</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease-related&#xD;
&#xD;
          1. Patient is a newly diagnosed MM patient.&#xD;
&#xD;
          2. Patient is age ≥ 65 year of age or who are ineligible for autologous stem cell&#xD;
             transplantation.&#xD;
&#xD;
          3. Patient has measurable disease, defined as follows: any quantifiable serum monoclonal&#xD;
             protein value (generally, but not necessarily, ≥ 0.5 g/dL of M-protein) and, where&#xD;
             applicable, urine light-chain excretion of &gt; 200 mg/24 hours. For patients with oligo-&#xD;
             or non-secretory MM, it is required that they have measurable plasmacytoma &gt; 2 cm as&#xD;
             determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an&#xD;
             abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of&#xD;
             patients admitted to this study will be oligo- or non-secretory MM with free light&#xD;
             chains only in order to maximize interpretation of benefit results.&#xD;
&#xD;
             Demographic:&#xD;
&#xD;
          4. Age ≥ 18 years.&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix F).&#xD;
&#xD;
             Laboratory:&#xD;
&#xD;
          7. Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and&#xD;
             serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 14 days prior to randomization.&#xD;
&#xD;
          8. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L within 14 days prior to randomization.&#xD;
&#xD;
          9. Corrected serum calcium ≤ 14 mg/dL (3.5 mmol/L).&#xD;
&#xD;
         10. Alanine transaminase (ALT): ≤ 3 x the ULN.&#xD;
&#xD;
         11. Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be&#xD;
             receiving red blood cell [RBC] transfusions in accordance with institutional&#xD;
             guidelines).&#xD;
&#xD;
         12. Platelet count ≥ 50 × 109/L (≥ 30 × 109/L if myeloma involvement in the bone marrow is&#xD;
             &gt; 50%) within 14 days prior to randomization.&#xD;
&#xD;
         13. Creatinine clearance (CrCl) ≥ 15 mL/minute within 7 days prior to randomization,&#xD;
             either measured or calculated using a standard formula (eg, Cockcroft and Gault).&#xD;
&#xD;
             Ethical/Other:&#xD;
&#xD;
         14. Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
         15. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and&#xD;
             to practice contraception.&#xD;
&#xD;
         16. Male subjects must agree to practice contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Disease-related:&#xD;
&#xD;
          1. Previous treatment with anti-myeloma therapy (does not include radiotherapy,&#xD;
             bisphosphonates, or a single short course of steroid; ≤ to the equivalent of&#xD;
             dexamethasone 40 mg/day for 4 days)&#xD;
&#xD;
          2. Patient with relapsed or refractory multiple myeloma.&#xD;
&#xD;
          3. Patients with non-secretory MM unless serum free light chains are present and the&#xD;
             ratio is abnormal.&#xD;
&#xD;
             Concurrent Conditions:&#xD;
&#xD;
          4. Pregnant or lactating females (Appendix I).&#xD;
&#xD;
          5. Major surgery within 21 days prior to randomization.&#xD;
&#xD;
          6. Acute active infection requiring treatment (systemic antibiotics, antivirals, or&#xD;
             antifungals) within 14 days prior to randomization.&#xD;
&#xD;
          7. Known human immunodeficiency virus infection.&#xD;
&#xD;
          8. Active hepatitis B or C infection.&#xD;
&#xD;
          9. Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA&#xD;
             Class III or IV heart failure, uncontrolled angina, history of severe coronary artery&#xD;
             disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or&#xD;
             electrocardiographic evidence of acute ischemia or Grade 3 conduction system&#xD;
             abnormalities unless subject has a pacemaker.&#xD;
&#xD;
         10. Uncontrolled hypertension, uncontrolled congestive heart failure (CHF) or uncontrolled&#xD;
             diabetes within 14 days prior to randomization.&#xD;
&#xD;
         11. Non-hematologic malignancy within the past 3 years with the exception of a) adequately&#xD;
             treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)&#xD;
             carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or&#xD;
             less with stable prostate-specific antigen levels; or d) cancer considered cured by&#xD;
             surgical resection or unlikely to impact survival during the duration of the study,&#xD;
             such as localized transitional cell carcinoma of the bladder or benign tumors of the&#xD;
             adrenal or pancreas.&#xD;
&#xD;
         12. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to&#xD;
             randomization.&#xD;
&#xD;
         13. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize&#xD;
             carfilzomib).&#xD;
&#xD;
         14. Contraindication to any of the required concomitant drugs or supportive treatments,&#xD;
             including hypersensitivity to all anticoagulation and antiplatelet options, antiviral&#xD;
             drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.&#xD;
&#xD;
         15. Subjects with pleural effusions requiring thoracentesis or ascites requiring&#xD;
             paracentesis within 14 days prior to randomization.&#xD;
&#xD;
         16. Any other clinically significant medical disease or condition that, in the&#xD;
             Investigator's opinion, may interfere with protocol adherence or a subject's ability&#xD;
             to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione EMN Italy Onlus</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Weekly</keyword>
  <keyword>CCyd</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

